[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8FJ-TKEzNC9Sr_UP2o8BOV86HK-g5RqOQlW_gmcEqY0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":84,"rows":91},"CHU de Quebec-Universite Laval",[4],136,false,38,8,79495,19,92,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Prostate Cancer",14,{"name":18,"count":19},"Traumatic Brain Injury",4,{"name":21,"count":19},"Insomnia",{"name":23,"count":19},"Bone Health",{"name":25,"count":19},"Breast Cancer",{"name":27,"count":19},"Quality of Life",{"name":29,"count":19},"Preeclampsia",{"name":31,"count":32},"Diabetes Mellitus, Type 1",3,[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT01653925","Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression","2016-12-31","Drug (Dutasteride) intervention first",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04171661","Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa","2019-12-24","SASS",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03753334","Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.","2023-12-12","MAG-EPA",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04009967","Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning","2024-09-01","Pembrolizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04862260","Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","2025-01-31","Cholesterol metabolism disruption",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT02754297","Personalized PRRT of Neuroendocrine Tumors","2025-04-12","177Lu-Octreotate",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04655365","Detecting Metastases by PyL PET\u002FCT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.","2025-11-01","Enzalutamide",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05327647","A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","2026-09-01","Bicalutamide",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06884540","Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial","2027-04","Dexmedetomidine",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT02350205","SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma","2028-01","Self assembled skin substitute",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,124,142,160,188,209,230,260,278,300,321,344,362,386,408,429,458,479,508,526,589,615,641,659,687,705,731,749,779,797,823,841,859,877,904,922,952,988,1015,1033,1058,1088,1106,1133,1159,1185,1212,1230,1254,1279,1304,1328,1354,1378,1402,1427,1456,1474,1492],{"intervention":93,"totalTrials":94,"cells":95},"Target trough IgG level of 8-10 g\u002FL",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":122},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT07094048","Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager","RECRUITING",[89],"2028-12","2029-12","2026-01-05",80,[117,118],"Multiple Myeloma Refractory","Relapsed Multiple Myeloma",[93,120,121],"Target trough IgG level 4-6 g\u002FL","No history of recurrent or severe infections and total IgG level higher or equal at 4 g\u002FL",{"trials":123,"activeCount":98},[],{"intervention":120,"totalTrials":94,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":98},[],{"trials":129,"activeCount":98},[],{"trials":131,"activeCount":98},[],{"trials":133,"activeCount":98},[],{"trials":135,"activeCount":94,"soonestReadout":112},[136],{"nctId":108,"briefTitle":109,"status":110,"phases":137,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":138,"interventions":139},[89],[117,118],[93,120,121],{"trials":141,"activeCount":98},[],{"intervention":121,"totalTrials":94,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":158},{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":98},[],{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":94,"soonestReadout":112},[154],{"nctId":108,"briefTitle":109,"status":110,"phases":155,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":156,"interventions":157},[89],[117,118],[93,120,121],{"trials":159,"activeCount":98},[],{"intervention":161,"totalTrials":94,"cells":162},"Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":182,"PHASE4":184,"NA":186},{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":94,"soonestReadout":173},[169],{"nctId":170,"briefTitle":171,"status":110,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":181},"NCT07193134","GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment",[86,87],"2030-12","2035-12","2026-01-07",9,[178,179,180],"RDEB","Recessive Dystrophic Epidermolysis Bullosa","Epidermolysis Bullosa Dystrophica, Recessive",[161],{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"intervention":68,"totalTrials":94,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":191,"activeCount":98},[],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":94,"soonestReadout":67},[196],{"nctId":65,"briefTitle":66,"status":197,"phases":198,"primaryCompletion":67,"completion":72,"start":199,"enrollment":200,"conditions":201,"interventions":202},"ACTIVE_NOT_RECRUITING",[87],"2022-03-22",50,[15],[68],{"trials":204,"activeCount":98},[],{"trials":206,"activeCount":98},[],{"trials":208,"activeCount":98},[],{"intervention":53,"totalTrials":94,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":94,"soonestReadout":52},[217],{"nctId":50,"briefTitle":51,"status":197,"phases":218,"primaryCompletion":52,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},[87],"2025-03-30","2020-01-10",30,[15],[53],{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"trials":229,"activeCount":98},[],{"intervention":231,"totalTrials":94,"cells":232},"177Lu-PSMA-I&T - escalating renal absorbed dose",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":94,"soonestReadout":244},[239],{"nctId":240,"briefTitle":241,"status":242,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":252},"NCT05896371","A Phase 1\u002F2 Study of Personalized PSMA Radiopharmaceutical Therapy","NOT_YET_RECRUITING",[86,87],"2033-03","2034-03","2028-03",500,[249,15,250,251],"Cancer","Metastatic Cancer","Metastatic Prostate Cancer",[231,253],"177Lu-PSMA-I&T - recommended phase 2 regime",{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":98},[],{"intervention":253,"totalTrials":94,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":263,"activeCount":98},[],{"trials":265,"activeCount":98},[],{"trials":267,"activeCount":94,"soonestReadout":244},[268],{"nctId":240,"briefTitle":241,"status":242,"phases":269,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":270,"interventions":271},[86,87],[249,15,250,251],[231,253],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":94,"soonestReadout":82},[286],{"nctId":80,"briefTitle":81,"status":110,"phases":287,"primaryCompletion":82,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},[86,87],"2029-01","2015-12",52,[292],"Burns",[83],{"trials":295,"activeCount":98},[],{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"intervention":48,"totalTrials":94,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":94,"soonestReadout":47},[308],{"nctId":45,"briefTitle":46,"status":197,"phases":309,"primaryCompletion":47,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},[87],"2026-12","2017-07-10",39,[15],[48],{"trials":316,"activeCount":98},[],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":94,"soonestReadout":72},[329],{"nctId":70,"briefTitle":71,"status":110,"phases":330,"primaryCompletion":72,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},[87],"2026-12-31","2022-06-23",160,[335],"Non-Muscle Invasive Bladder Cancer",[73,337],"Control Arm",{"trials":339,"activeCount":98},[],{"trials":341,"activeCount":98},[],{"trials":343,"activeCount":98},[],{"intervention":337,"totalTrials":94,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":347,"activeCount":98},[],{"trials":349,"activeCount":98},[],{"trials":351,"activeCount":94,"soonestReadout":72},[352],{"nctId":70,"briefTitle":71,"status":110,"phases":353,"primaryCompletion":72,"completion":331,"start":332,"enrollment":333,"conditions":354,"interventions":355},[87],[335],[73,337],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"intervention":63,"totalTrials":94,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":94,"soonestReadout":62},[370],{"nctId":60,"briefTitle":61,"status":197,"phases":371,"primaryCompletion":62,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":379},[87],"2029-04-12","2016-04-12",275,[376,377,378],"Neuroendocrine Tumors","Carcinoid Tumor","Carcinoma, Neuroendocrine",[63],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"intervention":58,"totalTrials":94,"cells":387},{"EARLY_PHASE1":388,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":389,"activeCount":94,"soonestReadout":57},[390],{"nctId":55,"briefTitle":56,"status":197,"phases":391,"primaryCompletion":57,"completion":331,"start":392,"enrollment":32,"conditions":393,"interventions":397},[85],"2021-10-04",[394,395,396,250],"Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer","Pancreas Cancer",[58],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"intervention":43,"totalTrials":94,"cells":409},{"EARLY_PHASE1":410,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":411,"activeCount":94,"soonestReadout":42},[412],{"nctId":40,"briefTitle":41,"status":197,"phases":413,"primaryCompletion":42,"completion":414,"start":415,"enrollment":94,"conditions":416,"interventions":418},[85],"2026-12-18","2019-12-10",[417],"Epidermolysis Bullosa Dystrophica",[43],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":98},[],{"trials":428,"activeCount":98},[],{"intervention":430,"totalTrials":94,"cells":431},"Androgen Deprivation Therapy",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":94,"soonestReadout":113},[444],{"nctId":445,"briefTitle":446,"status":242,"phases":447,"primaryCompletion":113,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":457},"NCT07483658","Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy\u002F25) Versus 20 Fractions (52.5 Gy\u002F20) for Recurrent Prostate Cancer After Surgery.",[90],"2036-02","2026-02",434,[452,453,15,454,455,456],"Reccurent\u002FMetastatic Solid Tumor Disease","Prostate Cancer (Post Prostatectomy)","Prostatic Neoplasms","Neoplasm Recurrence, Local","Biochemical Recurrence of Malignant Neoplasm of Prostate",[430],{"intervention":38,"totalTrials":94,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"trials":465,"activeCount":98},[],{"trials":467,"activeCount":98},[],{"trials":469,"activeCount":98},[],{"trials":471,"activeCount":94,"soonestReadout":37},[472],{"nctId":35,"briefTitle":36,"status":197,"phases":473,"primaryCompletion":37,"completion":310,"start":474,"enrollment":475,"conditions":476,"interventions":478},[90],"2010-10-28",120,[454,477],"Low Grade Prostate Cancer",[38],{"intervention":78,"totalTrials":94,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"trials":488,"activeCount":98},[],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":94,"soonestReadout":77},[493],{"nctId":75,"briefTitle":76,"status":110,"phases":494,"primaryCompletion":77,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":506},[90],"2027-10","2025-07-15",100,[499,500,501,27,502,503,504,505],"Anesthesia","Anesthesia Complication","Surgery","Pain, Postoperative","Anesthesia Morbidity","Feasibility Studies","Patient-centredness",[78,507],"lidocaine",{"intervention":507,"totalTrials":94,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":98},[],{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"trials":521,"activeCount":94,"soonestReadout":77},[522],{"nctId":75,"briefTitle":76,"status":110,"phases":523,"primaryCompletion":77,"completion":495,"start":496,"enrollment":497,"conditions":524,"interventions":525},[90],[499,500,501,27,502,503,504,505],[78,507],{"intervention":527,"totalTrials":19,"cells":528},"Placebos",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":561,"NA":587},{"trials":530,"activeCount":98},[],{"trials":532,"activeCount":98},[],{"trials":534,"activeCount":98},[],{"trials":536,"activeCount":98},[537,549],{"nctId":538,"briefTitle":539,"status":540,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":200,"conditions":545,"interventions":547},"NCT00317148","Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women","COMPLETED",[87,88],"2006-09","2007-12","2005-08",[546],"Hot Flashes",[527,548],"DHEA",{"nctId":550,"briefTitle":551,"status":540,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT00248989","Effect of DHEA on Skin Aging in Postmenopausal Women",[88],"2005-11-24","2008-11-13","2004-11-01",150,[558,27],"Skin Aging",[560,527],"Dehydroepiandrosterone",{"trials":562,"activeCount":98},[563,574],{"nctId":564,"briefTitle":565,"status":540,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT01787916","52 Week Trial of Liraglutide in Type 1 Diabetes",[89],"2015-04","2013-04",15,[571],"Type 1 Diabetes",[573,527],"Liraglutide",{"nctId":575,"briefTitle":576,"status":577,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT03809312","The Use of Prophylactic Antibiotics in Endoscopy Sinus Surgery for Chronic Rhinosinusitis With or Without Polyp","UNKNOWN",[89],"2020-12","2021-02","2019-08-14",134,[584],"Chronic Sinus Infection",[586,527],"Amoxicillin \u002F Clavulanic acid 875mg \u002F 125mg",{"trials":588,"activeCount":98},[],{"intervention":590,"totalTrials":94,"cells":591},"Dexamethasone",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":613},{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[602],{"nctId":603,"briefTitle":604,"status":605,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},"NCT02362321","Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma","TERMINATED",[89],"2009-05","2007-01",20,[611],"Hematoma, Subdural, Chronic",[590],{"trials":614,"activeCount":98},[],{"intervention":616,"totalTrials":94,"cells":617},"Vitamin D chewable tablet supplementation",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":639},{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"trials":625,"activeCount":98},[],{"trials":627,"activeCount":98},[628],{"nctId":629,"briefTitle":630,"status":540,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":8,"conditions":635,"interventions":637},"NCT02158598","Comparison of Changes in Serum 25(OH)D Concentrations Following Vitamin D Supplementation With Chewable Tablets Versus Pills",[89],"2017-12","2018-05-09","2014-06",[636],"Vitamin D Deficiency",[616,638],"Vitamin D pill supplementation",{"trials":640,"activeCount":98},[],{"intervention":638,"totalTrials":94,"cells":642},{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":657},{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[653],{"nctId":629,"briefTitle":630,"status":540,"phases":654,"primaryCompletion":632,"completion":633,"start":634,"enrollment":8,"conditions":655,"interventions":656},[89],[636],[616,638],{"trials":658,"activeCount":98},[],{"intervention":660,"totalTrials":94,"cells":661},"Monthly antibiotic",{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":685},{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":98},[],{"trials":669,"activeCount":98},[],{"trials":671,"activeCount":98},[672],{"nctId":673,"briefTitle":674,"status":540,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":683},"NCT01329588","Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers",[89],"2002-04","2001-03",636,[680,681,682],"Neisseria Gonorrhoeae Infection","Chlamydia Trachomatis","HIV",[660,684],"Monthly placebo",{"trials":686,"activeCount":98},[],{"intervention":684,"totalTrials":94,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":697,"NA":703},{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[699],{"nctId":673,"briefTitle":674,"status":540,"phases":700,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":701,"interventions":702},[89],[680,681,682],[660,684],{"trials":704,"activeCount":98},[],{"intervention":706,"totalTrials":94,"cells":707},"Anti-TNF suspended perioperatively",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":729},{"trials":709,"activeCount":98},[],{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[718],{"nctId":719,"briefTitle":720,"status":577,"phases":721,"primaryCompletion":722,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":727},"NCT02242474","Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis",[89],"2019-10","2015-07",660,[726],"Rheumatoid Arthritis",[706,728],"Anti-TNFα continued perioperatively",{"trials":730,"activeCount":98},[],{"intervention":728,"totalTrials":94,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":747},{"trials":734,"activeCount":98},[],{"trials":736,"activeCount":98},[],{"trials":738,"activeCount":98},[],{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[743],{"nctId":719,"briefTitle":720,"status":577,"phases":744,"primaryCompletion":722,"completion":722,"start":723,"enrollment":724,"conditions":745,"interventions":746},[89],[726],[706,728],{"trials":748,"activeCount":98},[],{"intervention":750,"totalTrials":94,"cells":751},"Acetylsalicylic Acid 160 mg",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":760,"NA":777},{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[],{"trials":761,"activeCount":98},[762],{"nctId":763,"briefTitle":764,"status":540,"phases":765,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":775},"NCT01352234","Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia",[89],"2014-12","2015-03","2011-09",104,[771,772,773,774],"Pre-Eclampsia","Fetal Growth Retardation","Premature Birth","Placental Insufficiency",[750,776],"Acetylsalicylic Acid 80 mg",{"trials":778,"activeCount":98},[],{"intervention":776,"totalTrials":94,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[791],{"nctId":763,"briefTitle":764,"status":540,"phases":792,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":793,"interventions":794},[89],[771,772,773,774],[750,776],{"trials":796,"activeCount":98},[],{"intervention":798,"totalTrials":94,"cells":799},"TasP using ART regimen as per Benin guidelines",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":821},{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[810],{"nctId":811,"briefTitle":812,"status":540,"phases":813,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":817,"interventions":819},"NCT02237027","Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin",[89],"2016-12","2014-10",361,[818],"Adherence to Medication Regime",[798,820],"PrEP using Truvada",{"trials":822,"activeCount":98},[],{"intervention":820,"totalTrials":94,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":839},{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[835],{"nctId":811,"briefTitle":812,"status":540,"phases":836,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":837,"interventions":838},[89],[818],[798,820],{"trials":840,"activeCount":98},[],{"intervention":573,"totalTrials":94,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":857},{"trials":844,"activeCount":98},[],{"trials":846,"activeCount":98},[],{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[],{"trials":852,"activeCount":98},[853],{"nctId":564,"briefTitle":565,"status":540,"phases":854,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":855,"interventions":856},[89],[571],[573,527],{"trials":858,"activeCount":98},[],{"intervention":586,"totalTrials":94,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":869,"NA":875},{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"trials":870,"activeCount":98},[871],{"nctId":575,"briefTitle":576,"status":577,"phases":872,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":873,"interventions":874},[89],[584],[586,527],{"trials":876,"activeCount":98},[],{"intervention":878,"totalTrials":94,"cells":879},"Generic latanoprost",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":902},{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[890],{"nctId":891,"briefTitle":892,"status":605,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":900},"NCT02047630","Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension",[89],"2014-12-04","2014-01",60,[898,899],"Primary Open Angle Glaucoma","Ocular Hypertension",[878,901],"Brand-name latanoprost",{"trials":903,"activeCount":98},[],{"intervention":901,"totalTrials":94,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[916],{"nctId":891,"briefTitle":892,"status":605,"phases":917,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":918,"interventions":919},[89],[898,899],[878,901],{"trials":921,"activeCount":98},[],{"intervention":548,"totalTrials":923,"cells":924},2,{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":940,"PHASE3":942,"PHASE4":948,"NA":950},{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[929],{"nctId":930,"briefTitle":931,"status":540,"phases":932,"primaryCompletion":933,"completion":934,"start":935,"enrollment":936,"conditions":937,"interventions":939},"NCT00429806","DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy",[86],"2007-03","2007-07","2006-11",40,[938],"Vaginal Atrophy",[548],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[944],{"nctId":538,"briefTitle":539,"status":540,"phases":945,"primaryCompletion":542,"completion":543,"start":544,"enrollment":200,"conditions":946,"interventions":947},[87,88],[546],[527,548],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[],{"intervention":953,"totalTrials":923,"cells":954},"Mirabegron",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":984,"NA":986},{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[963,974],{"nctId":964,"briefTitle":965,"status":540,"phases":966,"primaryCompletion":967,"completion":968,"start":568,"enrollment":969,"conditions":970,"interventions":973},"NCT02476175","Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder",[88],"2016-04","2016-06",35,[971,972],"Overactive Bladder","Urinary Incontinence",[953],{"nctId":975,"briefTitle":976,"status":540,"phases":977,"primaryCompletion":978,"completion":979,"start":568,"enrollment":980,"conditions":981,"interventions":982},"NCT02468830","Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder",[88],"2016-01","2016-03",58,[971,972],[983],"mirabegron",{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":98},[],{"intervention":989,"totalTrials":94,"cells":990},"Bifilact®",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":1011,"NA":1013},{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[999],{"nctId":1000,"briefTitle":1001,"status":540,"phases":1002,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1010},"NCT01839721","Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation",[88],"2010-11","2010-12","2006-12",246,[249,1008,1009,27],"Diarrhea","Abdominal Pain",[989],{"trials":1012,"activeCount":98},[],{"trials":1014,"activeCount":98},[],{"intervention":560,"totalTrials":94,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1029,"NA":1031},{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[1025],{"nctId":550,"briefTitle":551,"status":540,"phases":1026,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":1027,"interventions":1028},[88],[558,27],[560,527],{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[],{"intervention":1034,"totalTrials":94,"cells":1035},"Quadrivalent HPV vaccine",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1054,"NA":1056},{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[1044],{"nctId":1045,"briefTitle":1046,"status":540,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1053},"NCT02009800","ICI-VPH: Impact of HPV Immunisation Schedules Against HPV",[88],"2021-12","2013-11",3364,[1052],"Human Papillomavirus Infections",[1034],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[],{"intervention":1059,"totalTrials":94,"cells":1060},"pr Sandoz Tamsulosin",{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1084,"NA":1086},{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":98},[],{"trials":1068,"activeCount":98},[1069],{"nctId":1070,"briefTitle":1071,"status":577,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1082},"NCT05941806","Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection",[88],"2025-07-30","2023-08-01",220,[1077,1078,1079,1080,1081],"Urinary Retention","Colorectal Surgery","Rectal Resection","Post-operative Urinary Retention","Tamsulosin",[1059,1083],"Glucose",{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"intervention":1083,"totalTrials":94,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[1098],{"nctId":1070,"briefTitle":1071,"status":577,"phases":1099,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":1075,"conditions":1100,"interventions":1101},[88],[1077,1078,1079,1080,1081],[1059,1083],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"intervention":1107,"totalTrials":94,"cells":1108},"Trans-tympanic injection of a sodium thiosulfate gel",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[1115],{"nctId":1116,"briefTitle":1117,"status":605,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1126},"NCT02281006","Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity",[87],"2017-01-20","2015-01-01",13,[1123,1124,1125],"DDP","Head and Neck Cancer","Adverse Effect",[1107],{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":98},[],{"trials":1132,"activeCount":98},[],{"intervention":1134,"totalTrials":94,"cells":1135},"Bicalutamide 150 mg",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[1142],{"nctId":1143,"briefTitle":1144,"status":1145,"phases":1146,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":98,"conditions":1150,"interventions":1152},"NCT06018116","A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.","WITHDRAWN",[87],"2024-01-31","2024-02-12","2023-11-07",[1151],"Metastatic Urothelial Carcinoma",[1134],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[],{"intervention":1160,"totalTrials":94,"cells":1161},"Acetylsalicylic Acid",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[1168],{"nctId":1169,"briefTitle":1170,"status":540,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":200,"conditions":1175,"interventions":1178},"NCT02280031","Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.",[87],"2016-10","2016-11","2014-11",[1176,1177,772,29,773],"Small for Gestational Age","Infant, Very Low Birth Weight",[1160],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[],{"intervention":1186,"totalTrials":94,"cells":1187},"administration of a LHRH agonist and Bicalutamide",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1189,"activeCount":98},[],{"trials":1191,"activeCount":98},[],{"trials":1193,"activeCount":98},[1194],{"nctId":1195,"briefTitle":1196,"status":540,"phases":1197,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":896,"conditions":1201,"interventions":1204},"NCT00866554","Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy",[87],"2019-03","2019-12","2009-03",[15,1202,1203],"Erectile Dysfunction","Lower Urinary Tract Symptoms",[1186,1205],"administration of Bicalutamide, Dutasteride and Tamoxifen",{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"intervention":1205,"totalTrials":94,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[1220],{"nctId":1195,"briefTitle":1196,"status":540,"phases":1221,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":896,"conditions":1222,"interventions":1223},[87],[15,1202,1203],[1186,1205],{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"intervention":1231,"totalTrials":94,"cells":1232},"Tamsulosin Hydrochloride 0.4 MG",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[1239],{"nctId":1240,"briefTitle":1241,"status":577,"phases":1242,"primaryCompletion":1243,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1247},"NCT03314025","Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery",[87],"2022-10-01","2017-10-06",158,[1077],[1231],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"intervention":1255,"totalTrials":94,"cells":1256},"Methylphenidate HCl 10Mg SR",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[],{"trials":1262,"activeCount":98},[1263],{"nctId":1264,"briefTitle":1265,"status":605,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":609,"conditions":1269,"interventions":1272},"NCT02970500","Effect of Methylphenidate on Cancer-related Cognitive Impairment",[87],"2022-12-31","2017-10-09",[1270,1271],"Breast Cancer Female","Cancer-Related Condition",[1255],{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[],{"intervention":1280,"totalTrials":94,"cells":1281},"Myoblast transplantation",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[1288],{"nctId":1289,"briefTitle":1290,"status":577,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1297},"NCT02196467","Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients",[86,87],"2024-01","2014-05",10,[1296],"Duchenne Muscular Dystrophy",[1280],{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"intervention":1305,"totalTrials":94,"cells":1306},"Docetaxel",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[1313],{"nctId":1314,"briefTitle":1315,"status":605,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT00714376","Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients",[87],"2008-07","2008-05",6,[15],[1305],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[],{"intervention":1329,"totalTrials":94,"cells":1330},"sodium fluorescein injection 10%",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[1343],{"nctId":1344,"briefTitle":1345,"status":540,"phases":1346,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},"NCT02971800","Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy",[90],"2017-01","2017-04","2016-08",37,[1352],"Ureteral Injury",[1329],{"intervention":1355,"totalTrials":94,"cells":1356},"Vitamin D",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[1369],{"nctId":1370,"briefTitle":1371,"status":540,"phases":1372,"primaryCompletion":289,"completion":978,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT01493648","Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation",[90],"2011-12",78,[1376],"HMG COA Reductase Inhibitor Adverse Reaction",[1355],{"intervention":1379,"totalTrials":94,"cells":1380},"Cefazolin",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[1393],{"nctId":1394,"briefTitle":1395,"status":540,"phases":1396,"primaryCompletion":1397,"completion":415,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1401},"NCT04818931","Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy",[90],"2019-06-10","2018-04-07",326,[25],[1379],{"intervention":1403,"totalTrials":94,"cells":1404},"MMR vaccine \u002F MMRV vaccine",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[1417],{"nctId":1418,"briefTitle":1419,"status":577,"phases":1420,"primaryCompletion":1421,"completion":814,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT02712203","MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.",[],"2010-07","2004-07",5808,[1425],"Measles",[1403],{"intervention":1428,"totalTrials":94,"cells":1429},"4CMenb",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[1442],{"nctId":1443,"briefTitle":1444,"status":540,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT02712177","Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization",[],"2010-08","2019-04","2008-08",4535,[1451],"Meningococcal Infections",[1428,1453,1454,1455],"diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB","conjugated pneumococcal vaccine","MMRV",{"intervention":1453,"totalTrials":94,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[1470],{"nctId":1443,"briefTitle":1444,"status":540,"phases":1471,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1472,"interventions":1473},[],[1451],[1428,1453,1454,1455],{"intervention":1454,"totalTrials":94,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[1488],{"nctId":1443,"briefTitle":1444,"status":540,"phases":1489,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1490,"interventions":1491},[],[1451],[1428,1453,1454,1455],{"intervention":1455,"totalTrials":94,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[1506],{"nctId":1443,"briefTitle":1444,"status":540,"phases":1507,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1508,"interventions":1509},[],[1451],[1428,1453,1454,1455]]